BPC-157 and Anesthesia: Perioperative Interaction Guide

What is known about BPC-157 itself

BPC-157 is a synthetic peptide of 15 amino acids, described as a fragment of a protein first isolated from human gastric juice, and no FDA-approved drug contains it [1]. FDA's July 2026 review found its molecular targets have not been identified and its mechanisms 'remain poorly understood' [1]. A 2026 systematic review found 3 human studies with 30 patients in total, all of poor methodological quality, with certainty of evidence rated very low [3].

What the animal studies found

In 28-day intramuscular toxicity studies, BPC-157 shortened clotting time (aPTT) in rats and prolonged it in dogs, and the same studies found raised ALT, glucose and triglyceride levels; longer studies were not available [1].

In a 1997 rat experiment, intravenous BPC-157 had no effect on normal resting blood pressure but interfered with blood-pressure changes produced by L-NAME and L-arginine, two agents acting on the nitric oxide system [4]. That study did not test anesthetic drugs.

Does BPC-157 make anesthetic hypotension worse?

The human studies FDA identified were meeting abstracts, a retrospective chart review, a single-arm pilot and a 2-person pilot, and none of them examined blood pressure during anesthesia [1]. Spinal anesthesia lowers blood pressure on its own in some patients: in a prospective study of 952 patients, hypotension (systolic below 90 mmHg) developed in 314 (33%). That study did not involve BPC-157 and cannot say what the peptide adds [5].

The closest human record is a 2-person intravenous pilot: 10 mg on day 1 and 20 mg on day 2 in two adults, with vital signs and blood work checked before and after each infusion, and no side effects reported [6]. It did not test anesthesia, anesthetic drugs or perioperative blood pressure, so it does not establish how BPC-157 would behave around surgery [6].

Alcohol and anesthesia in mice

In mice, BPC-157 given before or after a large intraperitoneal ethanol dose (4 g/kg) opposed the acute intoxication that followed: the sustained anesthesia, hypothermia, rise in blood ethanol and deaths during the 90-minute observation period [7].

Dose and legal context

There is no FDA-approved dose because there is no approved product. Doses in the few published human reports include 2 to 4 mg injected into a knee, 10 mg injected around the bladder wall, and 10 mg then 20 mg given intravenously; none of these is a recommended dose [1].

BPC-157 is in none of the three categories on FDA's list of nominated bulk substances for state-licensed pharmacies and physicians [2]. On October 28, 2026, HHS filed a notice of a draft enforcement-discretion policy, which is not an approval and not binding. It says HHS does not intend to take enforcement action against certain state-licensed pharmacies and physicians that compound BPC-157 if the policy's conditions are met [8][9].